Milone and co-workers in November 1998, reported on a case of post-transplant thrombotic thrombocytopenic purpura (post-BMT-TTP) cured by multiple plasmaphereses (PP). 1 There are several reports that PP is the first-line therapy for patients with de novo TTP 2 while response is poor in post-BMT-TTP. 3 , 4 Milone and co-workers described a case of CML who developed a post-BMT-TTP on day +50; the patient underwent 19 PP up on day +70 but a complete clinical response was seen only on day +250. We hypothesize that spontaneous recovery of the disease occurred.
We observed a prompt response to high-dose immunoglobulins (HD-IG) in a 28-year-old man affected with ALL in first CR who underwent an unrelated BMT after a standard conditioning regimen with cyclophosphamide (120 mg/kg over 2 days i.v.) and TBI (12 Gy in six doses over 3 days); cyclosporin A (CsA) and methotrexate were given as GVHD prophylaxis: CsA (3 mg/kg) was given as a 12 h i.v. infusion from day −1 until the patient started eating. Then 6 mg/kg/day was given orally in two divided doses. Methotrexate was administered at the dose of 15 mg/m 2 on day +1 and then on day +3, +6, +11 at the dose of 10 mg/m 2 intravenously. Full graft take, defined as the second of 3 consecutive days with PMN Ͼ0.5 × 10 9 /l and platelets Ͼ25 × 10 9 /l, was documented on day +17; the patient was discharged on day +22 without evidence of acute GVHD.
On day +94 he developed a TTP syndrome characterized by joint pain, fever, anemia (Hb: 8 mg/dl), progressive platelet decrease to 10 × 10 9 /l and lactate dehydrogenase (LDH) levels as high as 1062 mg/dl; the CsA serum level was 192 g/dl. Blood smear examination showed the presence of red cell fragments; cultures of blood, sputum, urine, stool were negative as was standard chest radiography. The patient never showed signs of neurotoxicity nor nephrotoxicity (the maximum value of creatinemia was 1.5 mg/dl), or signs of acute GVHD. All data suggested a diagnosis of post-BMT-TTP grade 2 according to Zeigler's grading system. 4 On the basis of reported data in the literature 3, 4 showing an unsatisfactory response to PP in post-BMT-TTP, we planned to treat the patient with HD-IG. Immunoglobulins were administered at a dose of 400 mg/kg/day for 3 consecutive days; concomitantly, CsA was interrupted and steroids, at the dose of 1 mg/kg/day, were given. An unexpected resolution of symptoms was noticed early after one cycle of HD-IG. The patient was discharged 3 days later in remission. At discharge, LDH level was 450 mg/dl; platelet count was 80 × 10 9 /l. Two weeks later, fever, joint pain and platelet reduction occurred again; the patient received a second cycle of HD-IG with prompt resolution. At present he is well and in remission with a normal blood count at day +380 from transplant.
The peculiarity of this observation is the dramatic clinical remission of TTP probably related to the use of HD-IG. There are few data on the use of HD-IG in post-BMT-TTP which, moreover, may develop in patients receiving prophylactic immunoglobulins. Despite the wide overlap in clinical presentation, de novo and post-BMT-TTP show different responses to PP. The unsatisfactory results in patients with post-BMT-TTP could be due to a different pathogenesis of the disease; in post-BMT-TTP vascular damage may be related to the use of CsA, irradiation, intensive conditioning therapy, viral infections or GVHD which, in particular, may continue the vascular damage despite removal of other causative factors. 5 In this case we cannot establish if PP would have been effective; it probably would have been in the absence of concomitant acute GVHD. The unexpected response to HD-IG supports the hypothesis that they may neutralize an unknown platelet-aggregating factor. 6 The use of HD-IG in TTP is controversial: a case of response to HD-IG has been reported by Nosari et al 7 
while Finazzi et al
8 failed to demonstrate the efficacy of this approach in a prospective non-randomized comparative trial.
Although the use of HD-IG is expensive, its costs may be low compared with protracted PP. Since response can be evaluated within a few days, we advise an attempt to treat post-BMT-TTP by HD-IG.
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We have read with great interest the above letter from Alessandrino et al 'Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura'.
They describe the case of a 28-year-old man affected with ALL who underwent an unrelated BMT. On day +94 he developed a TTP syndrome without GVHD, and probably with no CMV infection, grade 2 according to Zeigler's grading system. These data make us think that perhaps the patient did not present a multifactorial TTP post-BMT and that this would be related to CsA. Consequently, CsA was interrupted and high doses of gammaglobulin were administered. Due to the quick complete remission and to the fact that it was an unrelated BMT it may be possible for the patient to restart with CsA before the TTP relapse.
In our case report 1 it is clear that the disease is a multifactorial TTP post-BMT (GVHD, CMV, CsA) stage 4 corresponding to Zeigler's classification and fulminating according to Pettit and Clark, 2 that would demonstrate clear response after 11 plasmaphereses with a decrease to grade 2 and a later complete remission on day +250. The CsA administration continues because the patient presents acute GVHD.
There is a clear prognostic difference between patients in stage 2 as in Alessandrino's case and patients in stage 4, TTP post-BMT as it is described in our report. 3 The literature shows that the use of high-dose immunoglobulins or plasma exchange is controversial. [4] [5] [6] [7] The TTP post-BMT is a disease with several etiologies and sometimes is multifactorial with not very well known mechanisms. This gives rise to much speculation and to no definite conclusions.
J Milone
ITMO-Fundacion Mainette-508 J Napal
E16 y 18 O Etchegoyen
Gonnet (1897) La Plata V Morales
Buenos Aires, Argentina
